Crucitti F, Doglietto G B, Bellantone R, Perri V, Tommasini O, Tonali P
Istituto di Patologia Speciale Chirurgica, Università Cattolica del Sacro Cuore, Rome, Italy.
J Surg Oncol. 1992 May;50(1):43-6. doi: 10.1002/jso.2930500113.
A retrospective study of 103 thymectomies examines the effects of the integration of surgical and medical therapy in patients affected by myasthenia gravis accompanied by thymoma. An extended thymectomy via a median longitudinal sternotomy was used in 102 patients. The operative mortality was 4.85% (5/103 patients), the 10-year survival rate was 78% with a recurrence rate of 3.06% (3/98). Neoplastic infiltration and postoperative radiotherapy did not influence the survival rate. There was no correlation between a preoperative Osserman's class better than III and postoperative outcome. The improvement of medical treatment, and anaesthesiological and intensive care techniques resulted in a decrease of the operative mortality and long-term death rate during the last 10 years of our 20-year series. Extended thymectomy via sternotomy is the best intervention in patients with myasthenia gravis associated with thymoma judged by the low operative mortality and the favorable 10-year survival rates.
一项对103例胸腺切除术的回顾性研究,探讨了手术和药物治疗相结合对伴有胸腺瘤的重症肌无力患者的影响。102例患者采用经胸骨正中纵切口的扩大胸腺切除术。手术死亡率为4.85%(103例患者中有5例),10年生存率为78%,复发率为3.06%(98例中有3例)。肿瘤浸润和术后放疗不影响生存率。术前Osserman分级优于III级与术后结果之间无相关性。在我们20年系列研究的最后10年中,药物治疗、麻醉和重症监护技术的改进导致手术死亡率和长期死亡率降低。经胸骨扩大胸腺切除术,因其手术死亡率低和10年生存率良好,被认为是伴有胸腺瘤的重症肌无力患者的最佳干预措施。